Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes

被引：0
|
作者：
Basho, Reva K.
Trevarton, Alex
Hess, Kenneth R.
Fu, Chunxiao
Lau, Rosanna
Lin, Chih-Hsu
Lichtarge, Olivier
Yang, Wei Tse
Symmans, William Fraser
Moulder, Stacy L.
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
588
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple negative breast cancer (TNBC)
    Krivorotko, P.
    Zhiltsova, E.
    Gigolaeva, L.
    Emelyanov, A.
    Pesotsky, R.
    Ereschenko, S.
    Levsghenko, V.
    Nikolaev, K.
    Komayachov, A.
    Ivanova, O.
    Tabagua, T.
    Zernov, K.
    Ivanov, V.
    Aseeva, Z.
    Bessonov, A.
    Semiglazov, V.
    BREAST, 2021, 56 : S52 - S52
  • [42] Combined PI3K and AURKA inhibition are efficacious in triple-negative breast cancer models
    Van Swearingen, Amanda E. D.
    Sambade, Maria J.
    Sud, Shivani
    Golitz, Brian
    Johnson, Gary L.
    Anders, Carey K.
    CANCER RESEARCH, 2016, 76
  • [43] Neoadjuvant chemotherapy (NACT) use and response in US patients with early-stage triple-negative breast cancer in the National Cancer Database (NCDB)
    Kashyap, M.
    Downer, M.
    Debiasi, M.
    Russell, K.
    Craggs, C.
    Luhn, P.
    Pollom, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S320 - S321
  • [44] Dual targeting of the PI3K-AKT pathway in triple-negative breast cancer
    Colley, Grace
    Eustace, Alexander
    AlSultan, Dalal
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
    Poggio, Francesca
    Bruzzone, Marco
    Ceppi, Marcello
    Ponde, Noam Falbel
    La Valle, Giovanni
    Sotiriou, Christos
    Del Mastro, Lucia
    De Azambuja, Evandro
    Lambertini, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer
    Sato, Natsuki
    Wakabayashi, Masayuki
    Nakatsuji, Masatoshi
    Kashiwagura, Haruka
    Shimoji, Naohiro
    Sakamoto, Shiho
    Ishida, Atsuko
    Lee, Jangsoon
    Lim, Bora
    Ueno, Naoto T.
    Ishihara, Hideki
    Inui, Takashi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 489 (04) : 484 - 489
  • [47] Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer
    Stover, Daniel G.
    Bell, Caitlin F.
    Tolaney, Sara M.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (03) : 6 - 12
  • [48] Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy
    Marra, Antonio
    Curigliano, Giuseppe
    CANCER JOURNAL, 2021, 27 (01): : 41 - 49
  • [49] Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer
    Masuda, Hiroko
    Baggerly, Keith A.
    Wang, Ying
    Zhang, Ya
    Gonzalez-Angulo, Ana M.
    Meric-Bernstam, Funda
    Valero, Vicente
    Lehmann, Brian D.
    Pietenpol, Jennifer A.
    Hortobagyi, Gabriel N.
    Symmans, William Fraser
    Ueno, Naoto T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Response to Neoadjuvant Chemotherapy of Triple Negative Breast Cancer
    Tokudome, N.
    Ito, Y.
    Takahashi, S.
    Sugihara, T.
    Hosonaga, M.
    Iwasaki, R.
    Hattori, M.
    Fukuda, T.
    Mitsuhashi, K.
    Kobayashi, K.
    Taira, S.
    Saito, Y.
    Fukada, I
    Ueki, N.
    Tsutsumi, C.
    Miyagi, Y.
    Iwase, T.
    Osako, T.
    Horii, R.
    Akiyama, F.
    Hatake, K.
    CANCER RESEARCH, 2009, 69 (24) : 571S - 572S
12345